- Home
- PNR vs EXEL Comparison
PNR vs EXEL Comparison
Compare PNR & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PNR | EXEL |
|---|---|---|
| Founded | 1966 | 1994 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.0B | 11.4B |
| IPO Year | 2003 | 2000 |
Fundamental Metrics
Financial Performance| Metric | PNR | EXEL |
|---|---|---|
| Price | $76.65 | $54.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 21 |
| Target Price | ★ $109.73 | $46.50 |
| AVG Volume (30 Days) | 2.0M | ★ 2.4M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.34% | N/A |
| EPS Growth | 5.88 | ★ 57.95 |
| EPS | ★ 1.05 | 0.79 |
| Revenue | N/A | ★ $452,477,000.00 |
| Revenue This Year | $4.24 | $13.61 |
| Revenue Next Year | $4.82 | $13.13 |
| P/E Ratio | $72.67 | ★ $68.70 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $69.93 | $33.76 |
| 52 Week High | $113.95 | $55.91 |
Technical Indicators
Market Signals| Indicator | PNR | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 56.74 | 63.78 |
| Support Level | $70.35 | $40.17 |
| Resistance Level | $91.13 | N/A |
| Average True Range (ATR) | 1.87 | 1.53 |
| MACD | 0.67 | 0.05 |
| Stochastic Oscillator | 86.05 | 73.19 |
Price Performance
Historical ComparisonAbout PNR Pentair plc.
Pentair is a global leader in the water treatment industry, with 10,000 employees and a presence in 25 countries. Its business is organized into three segments: pool, water technologies, and flow. The company offers a wide range of water solutions, including energy-efficient swimming pool equipment, filtration solutions, and commercial and industrial pumps. Pentair generated approximately $4.2 billion in revenue in 2025.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.